Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Transplant Cell Ther. 2022 Mar 15;28(6):325.e1–325.e7. doi: 10.1016/j.jtct.2022.03.014

Table 3.

Relative risk of late death for sickle cell disease

Variable Hazard Ratio (95% confidence interval) p-value
Age (10-year increment) 1.75 (1.29 – 2.40) 0.0004
Donor type
 HLA-matched sibling 1.00
 Alternative donor 3.49 (1.53 – 7.96) 0.0030
Sex
 Male 1.00
 Female 1.01 (0.47 – 2.15) 0.98
Performance score
 90 – 100 1.00
 ≤ 80 1.31 (0.53 – 3.22) 0.56
CMV serostatus
 Negative 1.00
 Positive 1.74 (0.68 – 4.42) 0.25
Conditioning regimen intensity
 Myeloablative 1.00 0.22
 Reduced-intensity 1.55 (0.58 – 4.12) 0.38
 Non-myeloablative 0.44 (0.11 – 1.74) 0.24
Graft type
 Bone marrow 1.00 0.44
 Peripheral blood 1.46 (0.59 – 3.61) 0.41
 Umbilical cord blood 0.59 (0.16 – 2.24) 0.44
Transplant period
 2011 – 2017 1.00
 2000 – 2010 1.12 (0.43 – 2.91) 0.82